Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

This article is authored by Dr YK Gupta, president, AIIMS, Jammu and Ankush Kapoor, founder & CEO, Pharma NXT Biotech.

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Reykjavik, Iceland Friday, March 21, 2025, 12:00 Hrs [IST] ...

South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...

A delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Mumbai-based Kilitch Drugs Ltd plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is ...